Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Pfizer's COVID-19 Oral Therapy To Be Tested In Hospitalized COVID-19 Patients In UK: Reuters

  • Pfizer Inc's (NYSE:PFE) oral COVID-19 therapy will be evaluated as a potential treatment for hospitalized COVID-19 patients in a major British trial.
  • A randomized study of potential medicines for COVID-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment.
  • "Paxlovid is a promising oral antiviral drug, but we don't know if it can improve survival of patients with severe COVID-19," said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial.
  • The scientists will assess if Pfizer's Paxlovid can reduce the risk of death among patients admitted to hospitals with COVID-19.
  • Related: Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized Patients.
  • RECOVERY, led by the University of Oxford, will also probe whether Paxlovid shortens the length of hospital stay or reduces the need for a mechanical ventilator.
  • Scientists behind the RECOVERY trial in 2020 showed that dexamethasone, a steroid, was able to save the lives of patients in a "major breakthrough" in the pandemic. They also discovered the effectiveness of treatments such as arthritis drug tocilizumab and antibody cocktail Ronapreve.
  • Price Action: PFE shares are up 0.74% at $53.17 during the market session on the last check Monday.
  • Photo by Diamond Rehab Thailand via Pixabay
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.